(395b) Targeting Lentivectors to Cd34+ Hematopoietic Stem Cells for Gene Therapy
AIChE Annual Meeting
2006
2006 Annual Meeting
Discovery, Development and Delivery of Medicines
Innovations in Biopharrmaceutical Development: Fast to Market, Short on Time II
Wednesday, November 15, 2006 - 12:50pm to 1:10pm
Targeted, virus mediated gene delivery holds the potential to treat previously un-curable diseases. Gene delivery to the common blood progenitor cells located in bone marrow, hematopoietic stem cells (HSCs), can provide a life-long source of a gene, therefore, a single injection may last a lifetime. To date, there are no publications claiming to successfully specifically target human primary HSCs in vivo or in vitro via the CD34 receptor, the sole reliable marker for human HSCs. Viral vectors are among the most efficient gene delivery machines. Recently, our group developed a new method to target genes to specific cell types in vivo using lentivectors (Yang et. al., 2006, PNAS 103:11479-11484). In order to target and deliver a gene using a lentivirus, cell binding and fusion must occur. Usually, binding and fusion are coupled at the same glycoprotein. Most previous attempts at targeted gene delivery have involved manipulating this glycoprotein by inserting targeting molecules into different locations within this glycoprotein or adding a ligand or antibody to bridge the virus to the cell. These methods have resulted in low viral titer, most likely due to the interruption of the natural binding or fusion of the virus, and are unacceptable for therapeutic applications. However, separating binding and fusion allows for increased specificity without decreasing the titer. Using an anti-CD34 antibody as a targeting molecule and a binding-deficient, fusion competent mutant of the Sindbus virus glycoprotein as a fusogen, we have been able to specifically target CD34+ cell lines both in vitro and in vivo. We have further shown that both the antibody and fusogen are required for infection. We are planning to test primary CD34+ cell targeting in vitro and eventually in vivo in a humanized mouse model.
Reference: Yang, L., Bailey, L., Baltimore, D., & Wang, P. (2006) Proc. Natl. Acad. Sci. USA 103, 11479-11484.
Checkout
This paper has an Extended Abstract file available; you must purchase the conference proceedings to access it.
Do you already own this?
Log In for instructions on accessing this content.
Pricing
Individuals
2006 Annual Meeting
AIChE Pro Members | $150.00 |
AIChE Graduate Student Members | Free |
AIChE Undergraduate Student Members | Free |
AIChE Explorer Members | $225.00 |
Non-Members | $225.00 |
Discovery, Development and Delivery of Medicines only
AIChE Pro Members | $100.00 |
Food, Pharmaceutical & Bioengineering Division Members | Free |
AIChE Graduate Student Members | Free |
AIChE Undergraduate Student Members | Free |
AIChE Explorer Members | $150.00 |
Non-Members | $150.00 |